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Nephron segment-specific inhibition of NaIK-ATPase activity by
cyclosporin A. Decreased kaliuresis and hyperkalemia are common
complications of cyclosporin A (CsA) therapy. If CsA significantly
inhibits renal tubular Na/K-ATPase activity, the alteration in trans-
epithelial K secretion and K homeostasis could result in hyperkale-
mia. To investigate this possibility, we tested the effects of CsA on
Na/K-ATPase activity in microdissected rat tubules. CsA, at a
"toxic" concentration of 600 ng/ml, significantly inhibited Na/K-
ATPase in cortical collecting ducts (CCD), medullary thick ascending
limbs (mTAL), and outer medullary collecting ducts from the outer
stripe (OMCD0) by 35%, 53%, and 39%, respectively. Cremophore, the
commercial vehicle for CsA, did not change Na/K-ATPase activity in
any nephron segment tested. To determine whether CsA inhibits
Na/K-ATPase activity in a dose-dependent manner, microdissected
CCD's were incubated with 300, 600, and 2500 nglml of CsA for 30
minutes. Na/K-ATPase activity was inhibited at 600 and 2500 ng/ml,
but not at 300 ng/ml. No further inhibition of enzyme activity was noted
at 2500 ng/ml. CsA did not change Na/K-ATPase activity in proximal
tubule SI, S2, and S3 subsegments; cortical thick ascending limbs
(cTAL), connecting tubules (CNT), or outer medullary collecting ducts
from the inner stripe (OMCD1). Prolonging the incubation of CsA with
S2 subsegments to 60 minutes did not result in inhibition of NaiK-
ATPase activity. Ouabain-insensitive ATPase activity was unaffected
by CsA or its vehicle in any nephron segment tested. In summary, CsA
specifically inhibits Na/K-ATPase activity in the CCD, mTAL, and
OMCDO. In the CCD, inhibition of Na/K-ATPase activity was
dose-dependent and occurred at concentrations commonly associated
with clinical CsA toxicity (600 to 2500 nglml). CsA-induced inhibition of
Na/K-ATPase activity in the CCD and OMCDO could decrease K
secretion and contribute to clinical hyperkalemia.
Cyclosporin A (CsA) is widely used to reduce the incidence
of renal transplant rejection [1, 2]. Although cyclosporin A
therapy has improved overall graft survival [1, 2] its use is
limited by potent nephrotoxicity [3] and hyperkalemia [4—8].
The mechanism of cyclosporin A-induced nephrotoxicity is
unknown. Acute cyclosporin A administration reduces glomer-
ular filtration rate by increasing afferent and efferent arteriolar
vasoconstriction and renal vascular resistance, thus decreasing
renal plasma flow [1, 2, 9]. Chronic cyclosporin A administra-
tion results in microvascular arteriolopathy, particularly of the
afferent arteriole, plus interstitial fibrosis, and vacuolization of
proximal tubule cells [10]. These effects are not limited to
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transplanted kidneys, but also occur in native kidneys of
patients being treated with cyclosporin A for non-renal diseases
[7, 11].
Cyclosporin A causes overt hyperkalemia and metabolic
acidosis. Clearance studies show that intraperitoneal adminis-
tration of CsA for one week to rats causes a distal tubular
acidification defect [12], and a significant reduction in sodium
and potassium excretion [13]. Cyclosporin A-treated rats also
have an impaired ability to excrete a potassium load, despite
serum potassium concentrations that exceed 8.4 mEq/liter [12].
CsA interferes with potassium homeostasis in humans as well
[14]. When CsA is infused into healthy volunteers, there is a
significant reduction in sodium and potassium excretion [15].
The decrease in kaliuresis and urinary acidification seen in
human and animal studies suggests that cyclosporin A may
interfere with distal tubule or collecting duct function.
Normal functioning of Na/K-ATPase is necessary for the
regulation of potassium excretion in the distal nephron [16].
Since CsA significantly inhibits Na/K-ATPase activity in rat
kidney cortical homogenates [17] and in human red blood cells
[18], CsA-induced hyperkalemia could be a consequence of
impaired potassium secretion and kaliuresis, ultimately arising
from cyclosporin A-induced inhibition of Na11K-ATPase ac-
tivity in potassium secreting nephron segments. The present
study examined how cyclosporin A affects Na/K-ATPase
activity in cortical and outer medullary nephron segments.
Methods
Tissue preparation
Pathogen-free male Sprague-Dawley rats (75 to 100 g) were
anesthetized with Nembutal (2 g!kg body weight i.p., Abbott
Laboratories, Chicago, Illinois, USA). The left kidney was
selectively perfused with 20 ml of ice-cold dissection solution
containing 1.0 mg/mI of collagenase (Type A, Boehringer Mann-
heim, Indianapolis, Indiana, USA) and albumin (BSA, fatty
acid free, 98 to 99% pure, Sigma Chemical Co., St. Louis,
Missouri, USA) as described previously [19]. The composition
of the dissection solution was (in mM): NaC1 137, KCI 5, MgSO4
0.8, Na2HPO4 0.33, KH2P0 0.44, MgC12 1, Tris-HCI 10, and
CaC12 0.25. Cortical and outer medullary slices were incubated
in a shaking water bath for 45 to 60 minutes at 37°C in 1 ml of
the collagenase solution described above. All tissue samples
were suffused with 100% 02 during the incubation process.
After incubation, the collagenase was removed, and tubules
were microdissected at 17°C using a dissecting microscope
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(Nikon SMZ-2B) and microforceps (Dumont #5). The following
segments were isolated: proximal tubule Si, S2, and S3 subseg-
ments, medullary thick ascending limbs (mTAL), cortical thick
ascending limbs (cTAL), connecting tubules (CNT), cortical
collecting ducts (CCD), and outer medullary collecting ducts
from the outer (0MCD0) or inner stripe (OMCDS).
Experimental protocol
Microdissected tubules from each rat were divided into four
groups: groups 1 and 2 were used to measure total and ouabain-
insensitive ATPase activity, respectively, while groups 3 and 4
were used to measure total and ouabain-insensitive ATPase
activity in the presence of cyclosporin A or vehicle. Na/K-
ATPase was calculated by subtracting ouabain-insensitive
ATPase activity from total ATPase activity.
Tubule transfer
The length (in mm) of microdissected tubules from each
nephron segment was measured using a calibrated eyepiece
micrometer and subsequently transferred into one of four
microcentrifuge tubes. Five to 10mm of tubule were transferred
into each tube. Tubule transfer was accomplished by adhering
the tubules to small glass beads (0.5 mm diameter, Thomas
Scientific Corp.) [19, 20], and then, using microforceps under
direct visualization, transferring the beads to the bottom of the
centrifuge tube containing a 1 d droplet of permeabilization
solution.
Permeabilization
Tubules were permeabilized by hypotonic shock, a rapid
freeze/thaw cycle, and imidazole treatment, then rapidly frozen
at —60°C for a minimum of 15 minutes in 1 l of a 1 mg/mI BSA
and 100 mt'i imidazole solution and then allowed to thaw to
room temperature. Optimal pernieabilization was achieved af-
ter repeating the above procedure three times.
Measurement of ATPase activity
Na/K-ATPase activity was measured under Vmax condi-
tions using the 32P method of Doucet, Katz and Morel [211, with
minor modifications. Enzyme activity was assayed directly in
the microcentrifuge tubes following incubation with one of two
incubation solutions. To measure total ATPase activity, tubules
(groups 1 and 3) were incubated in 1 1 of four times strength
incubation solution, yielding an incubation solution with the
following final concentrations (in mM): NaC1, 50; KCI, 5;
MgCl2, 10; EGTA, 1; Tris HC1, 100; Na2ATP, 10 (Grade II,
Sigma). To measure ouabain-insensitive ATPase activity
(groups 2 and 4), the incubation solution was identical to the
above except NaC1 and KCI were replaced by Tris HC1 and 1
mM ouabain (Sigma) was added [21, 22]. Cyclosporin A (1 d,
Sandimmune, Sandoz Corp., Basel, Switzerland) in final con-
centrations ranging from 300 to 2500 ng/ml, or vehicle (1 p1,
cremophore) was added to groups 3 and 4. (CsA concentrations
were determined by diluting the stock solution provided by
Sandoz.) All groups were incubated with 1 p1 of a 32P-ATP (10
Ci/mmol, New England Nuclear, Boston, Massachusetts, USA)
solution diluted to give approximately 5 nCi/liter. Distilled H20
was added to each group to achieve a final volume of 4 p1 and
then incubated in a shaking water bath at 37°C for 30 minutes,
except for some S2's which were incubated for 60 minutes
(Results). ATP hydrolysis was stopped by the addition of 280 p1
of an ice-cold mixture of 10% activated charcoal and 5%
trichloroacetic acid (Sigma). The microcentrifuge tubes were
vortexed vigorously for 15 seconds and then spun at 15,000 rpm
for 20 minutes. The supernatant, containing the hydrolyzed
radiolabeled P04, was removed and filtered directly through a
450 m nitrocellulose filter (Millipore Corp., France) into
scintillation vials. Filters were washed with 5 ml of distilled
H20 and the filtrate counted in a liquid scintillation counter.
Calculations
To determine the amount of spontaneously hydrolyzed ATP.
four blanks were incubated as described above with equal
volumes of incubation solution and radiolabeled ATP. This
background was subtracted from all groups prior to calculating
enzyme activity. The amount of total 32P-ATP added to each
group was determined for each experiment by averaging the
total amount of radioactivity from 4, 1 p1 aliquots of stock
32P-ATP solution. This number, in CPM, was used to calculate
the specific radioactivity of 32P-ATP in CPM/pmol ATP. En-
zyme activity for Na/K-ATPase and ouabain-insensitive
ATPase (Mg-ATPase) was reported in pmol ATP hydrolyzed
per mm tubule length per minute (pmol/mm/min) and calculated
from the following formula:
ATPase activity MR-B/SRA/tubule length/mm
where MR is measured radioactivity, B is background hydro-
lysis, and SRA is specific radioactivity. Background hydrolysis
averaged 7 to 10% of measured radioactivity.
Statistics
The results are presented as mean SE from paired experi-
ments. N indicates the number of rats studied. Statistical
significance was calculated by Student's r-test with a value ofF
<0.05 being significant. One-way analysis of variance was used
for comparisons between three groups, followed by a multiple
comparisons, protected t-test to determine which groups were
significantly different.
Results
Effect of cyclosporin A on Na/K-ATPase activity along the
nephron
The effect of cyclosporin A upon Na/K-ATPase activity
was investigated in proximal tubule Sl, S2, and S3 sub-
segments, mTALs, cTALs, CNTs, CCDs, OMCD0s, and
0MCD1s. Cyclosporin A (600 ng/ml, 30 mm incubation) signif-
icantly inhibited Na/K-ATPase activity by 55% in mTALs
(Fig. 1), 35% in CCDs (Fig. 2), and 39% in OMCD0s (Fig. 2).
Cyclosporin A (600 ng/ml) had no significant effect in the other
nephron segments studied (Figs. 1 and 2). Baseline Na/K-
ATPase activity was significantly higher in Si than in S2 or S3
(Fig. 1). Cyclosporin A had no significant effect on ouabain-
insensitive ATPase (Mg-ATPase) in any nephron segment stud-
ied (Fig. 3).
To determine whether the segment-specific sensitivity to
cyclosporin A could be due to differences in the time course of
the toxic process, we incubated additional S2s with cyclosporin
A for 60 minutes. Cyclosporin A still had no significant effect on
(N=6)E 3O
(N=7)
. 2SkTT
2O[ (N=7)
I(N=13)
J(N=9) (N 13)1:t
10 (N=6) I 1T11 (N=6) (N=7)a)
C0
5Ua-
a o
Si 82 53 mTAL cTAL Si S2 53 mTAL cTAL CNT CCD OMCD OMCDOs Is
(N=7)
60
50
40
30
(N=7)
20
10
(N=13) (N=9)
248 Tumlin and Sands: GSA inhibition of Na/K-ATPase
:1
E
>
a)(I)
Co
a-
I—
z
Fig. 1. Effect of cyclosporin A (600 nglml) upon Na/K-ATPase
activity along rat nephron. Cyclosporin A () significantly decreased
Na/K-ATPase activity in mTALs (*P <0.05). Vehicle was not added
to control groups (D). No effect was seen in cTALs or proximal tubule
subsegments. Na/K-ATPase activity was significantly higher in Si
than in S2 or S3 subsegments of the proximal tubule (P < 0.05 by
ANOVA).
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Fig. 2. Effect of cyclosporin A (600 nglml) upon Na/K-ATPase
activity in rat collecting duct segments. Vehicle was not added to
control groups (U). Cyclosporin A () significantly decreased Na/K-
ATPase activity in CCDs and OMCD0s (*P < 0.05).Cyclosporin A had
no effect in CNTs or OMCD,s.
Na/K-ATPase activity (control: 13.9 6.2 pmollmmlmin,
cyclosporin A: 10.2 4.1 pmoL'mm/min, N 5, P = NS).
Effect of vehicle on NaIK-ATPase activity along the
nephron
The effect of cyclosporin A's commercial vehicle (cremo-
phore) was tested in three nephron segments: two Which
showed inhibition by CsA (CCD, mTAL) and one which was
not inhibited by CsA (S2). Cremophore alone had no effect
upon Na/K-ATPase or Mg-ATPase activity in any nephron
segment (Fig. 4).
Cyclosporin A dose response in the CCD
To determine whether cyclosporin A inhibited Na/K-
ATPase activity in a dose-dependent manner, the effect of two
additional cyclosporin A concentrations was examined in
CCDs: a therapeutic cyclosporin A concentration (300 nglml)
Fig. 3. Effect of cyclosporin A (600 ng/ml) upon Mg-A TPase (ouabain-
insensitive ATPase) along rat nephron. Vehicle was not added to
control groups (D). Cyclosporin A ()had no effect upon Mg-ATPase
in any nephron segment tested.
Fig. 4. Effect of cyclosporin A's vehicle (cremophore), upon ATPase
activity in S2s, mTALs, and CCDs. Neither cyclosporin A nor vehicle.
was added to control groups (U). Vehicle () had no effect upon
Na/K-ATPase or Mg-ATPase in CCDs or mTALs, cyclosporin A
sensitive nephron segments, or S2s, a cyclosporin A insensitive
segment.
and a toxic cyclosporin A concentration (2500 tg/ml). At 300
ng/ml, cyclosporin A reduced Na/K-ATPase activity by
23%, but this inhibition was not statistically significant (Fig. 5).
At 2500 ng/ml, cyclosporin A significantly inhibited Na/K-
ATPase activity by 36% (Fig. 5). There was no difference in the
percent inhibition between 600 and 2500 ng/ml cyclosporin A
(Fig. 5).
Discussion
Our main result is that cyclosporin A inhibits Na/Kt
ATPase activity in microdissected rat CCDs, OMCD0s, and
mTALs. Cyclosporin A inhibited Na/K-ATPase activity by
35% in CCDs, 39% in OMCD0s, and 55% in mTALs. In CCDs,
the main nephron segment responsible for potassium secretion,
Na/K-ATPase activity was not inhibited by vehicle alone,
but was inhibited in a dose-dependent manner at concentrations
commonly associated with clinical cyclosporin A toxicity.
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Fig. 5. Cyclosporin A dose response in rat CCD. Na/K-ATPase
activity decreased significantly at 600 and 2500 ng/ml cyclosporin A (*P
< 0.05). Cyclosporin A () had no effect upon Na/K-ATPase
activity at 300 ng/ml or 0 ng/ml (addition of vehicle alone). Data for
Na/K-ATPase activity at 600 ng/ml and 0 ng/ml (vehicle) were
previously shown in Figures 1 and 4, respectively. Symbol (L) is for
controls.
While it is tempting to speculate that cyclosporin A-induced
inhibition of Na/K-ATPase activity would decrease potas-
sium secretion in CCDs (and OMCD0s), we cannot draw this
conclusion from the present data. Rather, we can conclude that
cyclosporin A inhibits Na/K-ATPase activity in a nephron
segment-specific manner.
Na/K-ATPase activity was measured under Vmax condi-
tions using a minor modification of the 32P method of Doucet et
al [211. Tubules were transferred under direct visualization into
microcentrifuge tubes and incubated in 4 1 of incubation
solution to minimize tubule loss and simplify membrane perme-
abilization. Our values for Na/K-ATPase activity were sim-
ilar to those reported by other investigators in all nephron
segments except cTALs [16]. We cannot explain this lone
discrepancy, however, the excellent agreement in the other
nephron segments suggests that our minor changes in method-
ology had no effect on experimental outcome.
Cyclosporin A has acute effects upon Na and K metabo-
lism in both human and animal models [6, 7, 12, 14, 23, 24].
Conti et al demonstrated in healthy volunteers that acute
administration of oral CsA (12.0 mg/kg) resulted in a significant
decrease in the fractional excretion of Na [25]. In a similar
study, Kamel et al investigated the effects of CsA upon K
excretion in renal transplant patients and found that when
compared to healthy controls, CsA therapy had no effect upon
K excretion during steady state conditions. However, treat-
ment with CsA resulted in a significantly decreased ability to
generate a transtubular potassium gradient (TTKG) following
infusion of KCI. This effect did not improve with exogenous
mineralocorticoids and led Kamel to speculate that CsA inhibits
the generation of electrochemical gradients in the distal
nephron [8].
Potassium secretion by the distal nephron is critically depen-
dent upon the activity of the Na/K-ATPase. Katz et al [16,
26] demonstrated that Na/K-ATPase activity in CCDs and
OMCDs increased approximately 300% in mice fed a potassium
rich diet. A small but significant increase in Na/K-ATPase
activity was also noted in mTALs [16, 26]. The increased
Na/K-ATPase activity in these nephron segments correlated
with a significant increase in urinary potassium excretion [26].
The physiologic importance of NaVK-ATPase to potassium
secretion is underscored by several studies which note that
potassium secretion in rabbit CCDs was ultimately dependent
upon Na/K-ATPase activity [27—29]. Stanton Ct al [30] also
demonstrated that potassium secretion in rats increased by
200% following K loading and noted a significant increase in
CCD and CNT basolateral membrane infolding [30]. Given the
similar physiologic functions and cell types in the CCD and
CNT, we were surprised that cyclosporin A did not inhibit
Na17K-ATPase activity in CNTs.
Two previous reports suggest that cyclosporin A inhibits
Na11K-ATPase activity. Suzuki et al found a 39% decrease in
Na/K-ATPase activity in renal cortical homogenates from
rats given cyclosporin A for 30 and 90 days; there was no
inhibition after 10 days (plasma [CsA] = 275 ng/ml) [17]. Ihara
et al showed that incubating human red blood cells with high
doses of cyclosporin A (2500 ng/ml) caused a small, but
statistically significant, inhibition of Na/K-ATPase [18]. The
inhibition of Na*/K±ATPase activity in Suzuki's study was
concurrent with significant interstitial fibrosis and tubular atro-
phy. It is therefore not clear whether the decrease in Na/K-
ATPase activity was due to a direct effect of CsA or secondary
to a loss of nephron mass. We demonstrated that CsA acutely
inhibits Na/K-ATPase activity in the CCD, OMCDOS and
mTAL within 30 minutes. These experiments were performed
in vitro in microdissected tubules and therefore could not be a
consequence of tubule loss.
Cyclosporin A also interferes with electrolyte transport in the
thick ascending limb of Henle (TAL). Micropuncture studies by
Gnutzman, Hering and Gutsche [31] demonstrated that acute
cyclosporin A administration results in increased intraluminal
concentrations of sodium and potassium in TALs. However,
neither the mechanism of this effect, nor the role of Na/K-
ATPase was investigated [31]. Our study shows significant
inhibition of Na7K-ATPase activity in mTALs, a segment
which is thought to reabsorb, rather than secrete, potassium.
We speculate that inhibition of Na/K-ATPase activity in this
segment could explain the hypomagnesemia which occurs in
patients receiving cyclosporin A [7], as magnesium reabsorp-
tion occurs primarily in the thick ascending limb by secondary
active transport linked to sodium and chloride reabsorption
[32].
Chronic cyclosporin A administration produces profound
structural and morphologic changes in proximal tubules in both
humans and animals. Vacuolization, mitochondrial swelling,
and atrophy can occur within three days of beginning cyclospo-
rin A therapy [10, 33]. Despite this, lithium clearance studies in
cyclosporin A treated rats have demonstrated increased rates of
sodium and potassium reabsorption by the proximal tubule [9].
We found that cyclosporin A (600 ng/ml) had no effect upon
Na/K-ATPase activity in any subsegment of the proximal
tubule. However, significant axial heterogeneity of NatIK-
ATPase activity was noted along the proximal tubule.
Cremophore, the vehicle for cyclosporin A, also has been
implicated in cyclosporin A-induced nephrotoxicity. Sokal et al
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demonstrated that cremophore disrupts transcellular pH gradi-
ents in primary cultures of rabbit proximal tubule cells [34]. The
pH gradient in these cultured cells is dependent upon Na/K-
ATPase activity [35]. Due to these reports, we performed
separate measurements of vehicle alone or cyclosporin A in
H20. We found no effect of cremophore upon Na/K-ATPase
activity in S2s, mTALs, or CCDs. Since neither CsA nor its
vehicle had any effect upon Na/K-ATPase or ouabain-
insensitive ATPase in the proximal tubule, cremophore may
only be toxic to cultured proximal tubule cells and not to native
epithelium.
Cyclosporin A-induced hyperkalemia appears to be a dose
dependent phenomenon. However, the correlation between
cyclosporin A toxicity and serum levels remains controversial.
Adu et al reported that 7 of 43 renal transplant patients
receiving cyclosporin A developed hyperkalemia and metabolic
acidosis, but found no correlation with drug levels [4]. In a
similar study, Foley, Flamner and Weinman found that hy-
perkalemia was more common in cyclosporin A treated patients
compared with azathioprine/prednisone treated patients [5].
However, in this study serum potassium did not correlate with
serum cyclosporin A levels [5], in contrast to Gupta et a! who
found that hyperkalemia and hyperuricemia do correlate with
cyclosporin A levels in patients receiving cyclosporin A for
treatment of psoriasis [7].
Therapeutic levels of cyclosporin A (300 ng/ml) had no
significant effect upon Na/K-ATPase activity, but concentra-
tions commonly seen with clinical cyclosporin A toxicity (600 to
2500 ng/ml) showed significant inhibition of enzyme activity.
Maximal inhibition of Na/KtATPase activity occurred at 600
ng/ml of cyclosporin A. This is in contrast to the in vivo studies
of Suzuki et al, who demonstrated that Na/K-ATPase activ-
ity in rat cortical homogenates was inhibited at lower plasma
concentrations of CsA (275 ng/ml) [17]. This discrepancy may
be explained by the observation of Kumar et al, who noted that
CsA levels in renal tissue were concentrated threefold above
whole blood levels following 10 days of therapy [361. Inhibition
of Na/K-ATPase activity in Suzuki's study would therefore
have occurred at renal CsA concentrations between 700 and 800
ng/ml, which is in general agreement with our in vitro results.
The mechanism(s) of cyclosporin A-induced inhibition Na/
K-ATPase activity is unknown. Suzuki et al noted that admin-
istering CsA to rats decreases the rate of 3H-thymidine and
3H-orotic acid incorporation into renal cortical tissue [17]. They
concluded that cyclosporin A inhibits Na/K-ATPase activity
by decreasing its rate of transcription and translation of new
enzyme. We found that cyclosporin A inhibits Na/K-ATPase
activity within 30 minutes, suggesting a direct effect upon
Na/K-ATPase activity, either by direct inhibition of the
enzyme, or by activation of secondary intracellular processes
which regulate activity.
Possible secondary mechanisms include cyclosporin A's ef-
fects upon arachidonic acid (AA) metabolism. Rats treated with
CsA for 10 days increase renal cytochrome P-450 metabolism of
arachidonic acid to 11, l2-dihydroxyeicosatrienoic acid [35, 37],
a potent inhibitor of Na/K-ATPase activity [38]. Schwartz-
man et al demonstrated that 30 to 40% of arachidonic acid
metabolism in the mTAL and CCD occurred through the P-450
pathway, and postulated that these metabolites play a role in
the physiologic regulation of Na47KtATPase activity. Thus,
selective cyclosporin A-induced inhibition of Na/K-ATPase
activity may be due to cytochrome P-450 metabolism of arachi-
donic acid in specific nephron segments.
Secondly, CsA-induced inhibition of Na/K-ATPase activ-
ity could result from a specific interaction between CsA and
isoforms of the enzyme's catalytic subunit. Three isoforms of
the alpha catalytic subunit have been described [39, 40], and
each differs markedly with respect to ouabain sensitivity [39],
Na affinity [41, 42], and tissue distribution [43—46]. Physio-
logic evidence for expression of different isoforms along the rat
nephron was provided by Barlet-Bas et a! who demonstrated
that Na affinity and ouabain sensitivity increase from the
proximal tubule to the CCD [471. The observation that ouabain-
sensitivity and Na affinity is greatest in the CCD led them to
speculate that alpha 2 and 3 isoforms are selectively expressed
in this nephron segment. A specific interaction between CsA
and different isoforms of the catalytic subunit could explain the
nephron specificity of CsA-induced inhibition of Na/K-
ATPase activity.
In conclusion, we have shown that cyclosporin A specifically
inhibits Na/K-ATPase activity in CCDs, OMCD0s, and
mTALs, nephron segments with important roles in potassium
and magnesium homeostasis. Inhibition of Na/K-ATPase
activity occurred in a dose dependent manner and was seen at
concentrations commonly associated with clinical cyclosporin
A toxicity. We propose that cyclosporin A-induced inhibition of
Na/K-ATPase activity may contribute to the clinical hy-
perkalemia and hypomagnesemia observed in patients treated
with cyclosporin A.
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